Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMD-1618
- Development stage
- Preclinical
- Lead developer
- Affinity Biopharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IMD-1618 is a bispecific antibody (bsAb) developed by Affinity Biopharmaceutical for the treatment of solid tumors. It is designed to simultaneously target Claudin-6 (CLDN6) and CD3. CLDN6 is a tight junction protein that is highly expressed in several types of cancer, such as ovarian and lung cancer, but has very low expression in normal adult tissues, making it a promising tumor-associated antigen. By binding to CD3 on T cells and CLDN6 on tumor cells, IMD-1618 acts as a T-cell engager, redirecting the cytotoxic activity of T cells to specifically eliminate CLDN6-expressing cancer cells. The drug is currently in preclinical development.
- Other names
- CLDN6 x CD3 bispecific antibodyCLDN-6 x CD3 bispecific antibodyCLDN 6 x CD3 bispecific antibodyCLDN6/CD3 bispecific antibody
02
Targets
CD3 (T-cell surface glycoprotein CD3)CLDN6 (Claudin-6)
Beyond the preview
Go deeper on IMD-1618.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMD-1618.